CN101862449A - 用于治疗念珠菌病的组合物和方法 - Google Patents
用于治疗念珠菌病的组合物和方法 Download PDFInfo
- Publication number
- CN101862449A CN101862449A CN201010200300A CN201010200300A CN101862449A CN 101862449 A CN101862449 A CN 101862449A CN 201010200300 A CN201010200300 A CN 201010200300A CN 201010200300 A CN201010200300 A CN 201010200300A CN 101862449 A CN101862449 A CN 101862449A
- Authority
- CN
- China
- Prior art keywords
- candida albicans
- purposes
- mice
- compositions
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title claims description 17
- 238000000034 method Methods 0.000 title description 8
- 229960005486 vaccine Drugs 0.000 claims abstract description 28
- 241000222122 Candida albicans Species 0.000 claims description 112
- 229940095731 candida albicans Drugs 0.000 claims description 88
- 208000015181 infectious disease Diseases 0.000 claims description 43
- 210000001647 gastrula Anatomy 0.000 claims description 36
- 210000000214 mouth Anatomy 0.000 claims description 35
- 239000006041 probiotic Substances 0.000 claims description 23
- 235000018291 probiotics Nutrition 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 12
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 8
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 230000009849 deactivation Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 5
- 201000010927 Mucositis Diseases 0.000 claims description 5
- 210000001989 nasopharynx Anatomy 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000002345 respiratory system Anatomy 0.000 claims description 5
- 208000003265 stomatitis Diseases 0.000 claims description 5
- 206010030216 Oesophagitis Diseases 0.000 claims description 3
- 208000006881 esophagitis Diseases 0.000 claims description 3
- 230000002688 persistence Effects 0.000 claims description 2
- 238000011284 combination treatment Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
- 229940126578 oral vaccine Drugs 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 63
- 238000011765 DBA/2 mouse Methods 0.000 description 60
- 206010007134 Candida infections Diseases 0.000 description 50
- 108010074328 Interferon-gamma Proteins 0.000 description 44
- 102100037850 Interferon gamma Human genes 0.000 description 43
- 108090000978 Interleukin-4 Proteins 0.000 description 41
- 102000004388 Interleukin-4 Human genes 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 41
- 238000011725 BALB/c mouse Methods 0.000 description 32
- 210000001744 T-lymphocyte Anatomy 0.000 description 29
- 201000003984 candidiasis Diseases 0.000 description 29
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 28
- 230000036039 immunity Effects 0.000 description 25
- 102000004127 Cytokines Human genes 0.000 description 20
- 108090000695 Cytokines Proteins 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 18
- 102000013462 Interleukin-12 Human genes 0.000 description 17
- 108010065805 Interleukin-12 Proteins 0.000 description 17
- 208000007027 Oral Candidiasis Diseases 0.000 description 15
- 210000002200 mouth mucosa Anatomy 0.000 description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 210000003296 saliva Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 210000005253 yeast cell Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 241000287411 Turdidae Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229940097572 chloromycetin Drugs 0.000 description 2
- 208000004264 complement component 5 deficiency Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 201000005655 esophageal candidiasis Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010010 raising Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101100046775 Arabidopsis thaliana TPPA gene Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010017938 Gastrointestinal candidiasis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 101100232925 Mus musculus Il4 gene Proteins 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000036732 invasive candidiasis Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ8214A AUPQ821400A0 (en) | 2000-06-19 | 2000-06-19 | Composition and methods for treatment of candidiasis |
| AUPQ8214 | 2000-06-19 | ||
| AUPQ8294 | 2000-06-22 | ||
| AUPQ8294A AUPQ829400A0 (en) | 2000-06-22 | 2000-06-22 | Compositions and methods for treatment of candidiasis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01812991A Division CN1443075A (zh) | 2000-06-19 | 2001-06-19 | 用于治疗念珠菌病的组合物和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101862449A true CN101862449A (zh) | 2010-10-20 |
Family
ID=25646360
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010200300A Pending CN101862449A (zh) | 2000-06-19 | 2001-06-19 | 用于治疗念珠菌病的组合物和方法 |
| CN01812991A Pending CN1443075A (zh) | 2000-06-19 | 2001-06-19 | 用于治疗念珠菌病的组合物和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01812991A Pending CN1443075A (zh) | 2000-06-19 | 2001-06-19 | 用于治疗念珠菌病的组合物和方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7655248B2 (enExample) |
| EP (1) | EP1303300B1 (enExample) |
| JP (1) | JP4933714B2 (enExample) |
| KR (1) | KR20030016298A (enExample) |
| CN (2) | CN101862449A (enExample) |
| AT (1) | ATE476987T1 (enExample) |
| BR (1) | BR0111785A (enExample) |
| CA (1) | CA2411912C (enExample) |
| DE (1) | DE60142786D1 (enExample) |
| WO (1) | WO2001097836A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6146411A (en) * | 1998-12-24 | 2000-11-14 | Alsius Corporation | Cooling system for indwelling heat exchange catheter |
| AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
| CN101060852A (zh) * | 2004-08-17 | 2007-10-24 | 亨特免疫有限公司 | 口服灭活疫苗及其提供方法 |
| EP1723965A1 (en) * | 2005-05-18 | 2006-11-22 | Stallergenes Sa | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
| WO2009013972A1 (ja) * | 2007-07-24 | 2009-01-29 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | 免疫アジュバント及びＩｇＡ抗体測定方法 |
| US9180173B2 (en) * | 2013-12-09 | 2015-11-10 | Stephanie D. Neider | Methods of treating psoriasis using candida antigen |
| FR3048361B1 (fr) * | 2016-03-01 | 2020-12-18 | Biose | Compositions pour le traitement des candidoses |
| CN106635849A (zh) * | 2016-11-15 | 2017-05-10 | 河北工程大学 | 一种白色念珠菌感染鸡模型建立的方法 |
| US11273190B2 (en) * | 2019-05-06 | 2022-03-15 | Kenda Rigdon | Composition of heat-killed yeast and taurine or a phytomedicine for the treatment of chronic inflammation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2397839A1 (fr) * | 1977-07-18 | 1979-02-16 | Grimberg Georges | Compose donnant un vaccin oral intestinal |
| CH680192A5 (enExample) * | 1989-12-13 | 1992-07-15 | Nestle Sa | |
| JP3510639B2 (ja) * | 1991-06-28 | 2004-03-29 | カルピス株式会社 | インターロイキン産生能を調節する機能を持たせた機能性食品又は健康食品 |
| GB9417880D0 (en) * | 1994-09-06 | 1994-10-26 | Auspharm Int Ltd | Vaccine |
| US5811249A (en) * | 1994-10-21 | 1998-09-22 | University Of Utah Research Foundation | Control of infectious microorganisms by modulation of chorionic gonadotropin-related protein activity |
| US5661377A (en) | 1995-02-17 | 1997-08-26 | Intraop Medical, Inc. | Microwave power control apparatus for linear accelerator using hybrid junctions |
| JPH09110707A (ja) * | 1995-10-12 | 1997-04-28 | Wakamoto Pharmaceut Co Ltd | 慢性腎不全改善剤および透析患者のクオリティー オブ ライフ改善剤 |
| US5902578A (en) * | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
| US5858378A (en) * | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| EP0834322A3 (en) * | 1996-10-04 | 1998-04-22 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Mycosis vaccine |
| JPH10139674A (ja) * | 1996-11-11 | 1998-05-26 | Yakult Honsha Co Ltd | インターロイキン１２産生促進剤 |
| US5869290A (en) * | 1996-11-21 | 1999-02-09 | Smithkline Beecham Corporation | Cayae1 polynucleotides |
| WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
| ATE207755T1 (de) * | 1998-04-30 | 2001-11-15 | Vesely Renata Maria Cavaliere | Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen |
| US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
-
2001
- 2001-06-19 BR BR0111785-8A patent/BR0111785A/pt not_active Application Discontinuation
- 2001-06-19 WO PCT/AU2001/000725 patent/WO2001097836A1/en not_active Ceased
- 2001-06-19 AT AT01942899T patent/ATE476987T1/de not_active IP Right Cessation
- 2001-06-19 DE DE60142786T patent/DE60142786D1/de not_active Expired - Lifetime
- 2001-06-19 CN CN201010200300A patent/CN101862449A/zh active Pending
- 2001-06-19 KR KR1020027017318A patent/KR20030016298A/ko not_active Withdrawn
- 2001-06-19 CN CN01812991A patent/CN1443075A/zh active Pending
- 2001-06-19 US US10/311,837 patent/US7655248B2/en not_active Expired - Fee Related
- 2001-06-19 EP EP01942899A patent/EP1303300B1/en not_active Expired - Lifetime
- 2001-06-19 JP JP2002503320A patent/JP4933714B2/ja not_active Expired - Fee Related
- 2001-06-19 CA CA2411912A patent/CA2411912C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004502653A (ja) | 2004-01-29 |
| US7655248B2 (en) | 2010-02-02 |
| DE60142786D1 (de) | 2010-09-23 |
| BR0111785A (pt) | 2003-05-20 |
| EP1303300A1 (en) | 2003-04-23 |
| CA2411912A1 (en) | 2001-12-27 |
| EP1303300A4 (en) | 2004-03-24 |
| EP1303300B1 (en) | 2010-08-11 |
| CA2411912C (en) | 2014-06-17 |
| CN1443075A (zh) | 2003-09-17 |
| ATE476987T1 (de) | 2010-08-15 |
| US20040037854A1 (en) | 2004-02-26 |
| KR20030016298A (ko) | 2003-02-26 |
| WO2001097836A1 (en) | 2001-12-27 |
| JP4933714B2 (ja) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7097838B2 (ja) | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 | |
| Kim et al. | Cytokine expression in leucocytes and gut cells of rainbow trout, Oncorhynchus mykiss Walbaum, induced by probiotics | |
| Shanahan | The host–microbe interface within the gut | |
| Arnold et al. | Tolerance rather than immunity protects from Helicobacter pylori–induced gastric preneoplasia | |
| Romani et al. | IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. | |
| Effros | Role of T lymphocyte replicative senescence in vaccine efficacy | |
| Zhan et al. | Differential induction of macrophage-derived cytokines by live and dead intracellular bacteria in vitro | |
| Wang et al. | Subcutaneous vaccination with Porphyromonas gingivalis ameliorates periodontitis by modulating Th17/Treg imbalance in a murine model | |
| Stanfield et al. | Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses | |
| Kubota et al. | Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates | |
| Yang et al. | Toxoplasma gondii α‐amylase deletion mutant is a promising vaccine against acute and chronic toxoplasmosis | |
| CN115820488B (zh) | 可调节幼鼠Th1/Th2平衡及IgA合成的长双歧杆菌婴儿亚种及其应用 | |
| CN111744003A (zh) | 趋化因子cx3cl1在制备疫苗中的应用和幽门螺旋杆菌疫苗 | |
| JP4933714B2 (ja) | カンジダ症の治療のための組成物および方法 | |
| CN120818452A (zh) | 鼠李糖乳酪杆菌在制备防治炎症性肠病产品中的用途 | |
| Fauser et al. | T-lymphocyte cytokine mRNA expression in cystic echinococcosis | |
| AU2001265694B2 (en) | Compositions and methods for treatment of candidiasis | |
| CN101155596B (zh) | 引发抗禽分枝杆菌副结核亚种的免疫应答的组合物 | |
| Alrobai et al. | An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine | |
| Lovett | Analysis of the Cervicovaginal Microbiome in Neisseria Gonorrhoeae Infections and Its Contribution to Disease Presentation | |
| AU2001265694A1 (en) | Compositions and methods for treatment of candidiasis | |
| US20020031519A1 (en) | Method of augmenting t cell-mediated immunity against toxoplasma gondii | |
| CN121160467A (zh) | 弓形虫me49δrasp1减毒疫苗株及其制备方法和应用 | |
| Alderete | Trichomonas vaginalis, a model mucosal parasite | |
| Sawamura et al. | The role of intestinal bacterial flora in the tuning of the T cell repertoire |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20101020 |